AI Drug Discovery
Sep 09, 2026 · 1 min read · 21,050 views
Nvidia-backed Iambic files for IPO, disclosing new clinic and dealmaking details
A
Aiden Brooks
Editorial · Sep 09, 2026
Iambic Therapeutics has filed to go public, the latest example in the maturation of the next crop of AI-focused biotech startups. The San Diego-based company disclosed new details on its own pipeline programs and pharma
← Previous
Gilead gets another HIV treatment approval, extending lenacapavir's dominance
Next →
Moderna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins
Related Reading
AI Drug Discovery
After years of hype, the first AI-designed drugs fall short in the clinic
Sep 27, 2026
AI Drug Discovery
A federal AI experiment could transform chronic care - if doctors and patients want it
Sep 24, 2026
Industry Insights
Post-Hoc Live: How much is everyone in biopharma getting paid?
Sep 28, 2026